CSF Aβ(42) and tau biomarkers in cognitively unimpaired Aβ- middle-aged and older APOE ε4 carriers
- Author(s)
- Lim, YY; Yassi, N; Bransby, L; Ayton, S; Buckley, RF; Eratne, D; Velakoulis, D; Li, QX; Fowler, C; Masters, CL; Maruff, P;
- Journal Title
- Neurobiology of Aging
- Abstract
- This study aimed to determine the relationship between the apolipoprotein E (APOE) ε4 allele and cerebrospinal fluid (CSF) and neuroimaging biomarkers of Alzheimer's disease, and cognition in cognitively unimpaired (CU) middle-aged adults (n = 82; M(age) = 58.2), and in Aβ- CU older adults (n = 71; M(age) = 71.8). Aβ- CU middle-aged ε4 carriers showed lower CSF Aβ(42) levels, higher levels of CSF total tau (t-tau) and neurofilament light (NfL), and poorer cognitive performance compared to noncarriers (Cohen's d: 0.30-0.56). In Aβ- CU older adults, ε4 carriers also had lower CSF Aβ(42) levels and higher levels of CSF t-tau and p-tau181, compared to noncarriers (Cohen's d: 0.65-0.74). In both Aβ- middle-aged and older adults, hippocampal and total brain volume were equivalent between ε4 carriers and noncarriers. In Aβ- CU middle-aged adults, APOE ε4 is associated with decreased levels of Aβ, increased tau and NfL, and poorer cognition. Similar relationships were observed in Aβ- CU older adults. These results have implications for understanding clinicopathological relationships between APOE ε4 and the emergence of cognitive and biomarker abnormalities in Aβ- adults.
- Publisher
- Elsevier
- Keywords
- Alzheimer’s disease; Amyloid; Apolipoprotein E; Cognition; Phosphorylated tau
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 37399739
- Publisher's Version
- https://doi.org/10.1016/j.neurobiolaging.2023.05.009
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-07-12 08:04:58
Last Modified: 2023-07-12 08:16:25